Dianthus Therapeutics, a US-based biotechnology company, announced on Tuesday that it has named Susan Kalled, PhD as its new chief scientific officer.

Kalled has decades of experience heading early discovery research, clinical drug development and strategic partnerships covering the areas of autoimmunity and inflammation, rare diseases and immuno-oncology. She has held the position of CSO of Compass Therapeutics, vice president of Biology at Q32 Bio and senior director of External Sciences at Shire. She started and advanced drug development efforts from discovery to clinical development, including CD40L and members of the BAFF family at the Immunology Research Group at Biogen.

Marino Garcia, Dianthus Therapeutics president and chief executive officer, said, 'We are thrilled to have Susan join the team at such a pivotal time for the company. Her expertise in shaping complement and immunology pipelines across small and large biotech companies will be invaluable as we advance our lead program through Phase 1 clinical studies this year and as we further develop our pipeline with novel targets and next-generation complement inhibitors.'